Home > Research > Publications & Outputs > Barriers to access to opioid medicines

Electronic data

  • Vranken Barriers to access to opioid medicines_resubmission2908_clean

    Rights statement: This is the author’s version of a work that was accepted for publication in The Lancet Oncology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in The Lancet Oncology, 17, 1, 2016 DOI: 10.1016/S1470-2045(15)00365-4

    Accepted author manuscript, 477 KB, PDF-document

    Available under license: CC BY-NC-ND: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Links

Text available via DOI:

View graph of relations

Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries

Research output: Contribution to journalJournal article

Published
  • Marjolein J. M. Vranken
  • John A. Lisman
  • Aukje K Mantel-Teeuwisse
  • Saskia Jünger
  • Willem Scholten
  • Lukas Radbruch
  • Sheila Alison Payne
  • Marie-Hélène D. B. Schutjens
Close
<mark>Journal publication date</mark>01/2016
<mark>Journal</mark>Lancet Oncology
Issue number1
Volume17
Number of pages10
Pages (from-to)e13-e22
StatePublished
Early online date23/12/15
Original languageEnglish

Abstract

Control measures designed to prevent the misuse of opioid medicines can often unintentionally restrict legitimate medical use, leaving patients with cancer in pain. This study aimed to develop and validate an assessment instrument based on WHO policy guidelines to systematically identify legal and regulatory barriers to opioid access in 11 European countries (Bulgaria, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Serbia, Slovakia, Slovenia, and Turkey) as part of the Access to Opioid Medication in Europe project. Relevant legislation and regulations were independently assessed by three reviewers and potential barriers were identified within nine categories including prescribing, penalties, and others. Potential barriers were identified in all countries, ranging from 22 potential barriers (Cyprus) to 128 potential barriers (Lithuania). The total number of barriers in a single category varied from one (Slovenia, usage category) to 49 (Greece, prescribing category). Differences, such as prescription validity, varied within one category, ranging from 5 days (Hungary) to 13 weeks (Cyprus). The results of this Review should give rise to a national review and revision of provisions that impede access to opioids, disproportionate to their (intended) benefit in preventing misuse, in these 11 European countries.

Bibliographic note

This is the author’s version of a work that was accepted for publication in The Lancet Oncology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in The Lancet Oncology, 17, 1, 2016 DOI: 10.1016/S1470-2045(15)00365-4